{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:47:02Z","timestamp":1792601222138,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec BV & Co KG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejca.2026.117781","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:10:07Z","timestamp":1792167007000},"page":"117781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Acute and long-term outcomes of CD20-targeting CAR T-cell therapy in relapsed or refractory B-NHL: MB-CART20.1 Lymphoma phase I trial"],"prefix":"10.1016","volume":"249","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-8575","authenticated-orcid":false,"given":"Nadine","family":"Kutsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-7626","authenticated-orcid":false,"given":"Hyatt","family":"Balke-Want","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6661-1237","authenticated-orcid":false,"given":"Stefanie","family":"Biedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-002X","authenticated-orcid":false,"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vu\u010dini\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentine Pia","family":"Altefrohne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kampfenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wennborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-1690","authenticated-orcid":false,"given":"Ben","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3782-2158","authenticated-orcid":false,"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"G\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117781_bib1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.117781_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117781_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117781_bib4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117781_bib5","series-title":"First two CAR-T cell medicines recommended for approval in the European Union","author":"European Medicines Agency","year":"2026"},{"key":"10.1016\/j.ejca.2026.117781_bib6","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/bloodadvances.2025016006","article-title":"Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia","volume":"9","author":"Yoon","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2026.117781_bib7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117781_bib8","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter's transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2026.117781_bib9","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.24.00033","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an international, multicenter, retrospective study","volume":"42","author":"Kittai","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117781_bib10","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.3324\/haematol.2023.284664","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma","volume":"109","author":"Benjamini","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2026.117781_bib11","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ejca.2026.117781_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/imed.1039","article-title":"The breakthrough and the future: CD20 chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"2","author":"Tan Su Yin","year":"2022","journal-title":"ImmunoMedicine"},{"key":"10.1016\/j.ejca.2026.117781_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.117781_bib14","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.117781_bib15","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Published November 27, 2017. Accessed October 5, 2026. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5\u00d77.pdf."},{"key":"10.1016\/j.ejca.2026.117781_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.117781_bib17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117781_bib18","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1182\/bloodadvances.2024014641","article-title":"Incidence of preexisting B-cell aplasia in B-ALL: implications for post-CAR T-cell monitoring","volume":"8","author":"Sahai","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2026.117781_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T-cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2026.117781_bib20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.117781_bib21","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.117781_bib22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ejca.2026.117781_bib23","article-title":"Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Zhang","year":"2016","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"10.1016\/j.ejca.2026.117781_bib24","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1200\/JCO.2024.42.16_suppl.7027","article-title":"A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"42","author":"Yan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117781_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-23-0263","article-title":"Long-term remissions following CD20-directed chimeric antigen receptor-adoptive T-cell therapy","volume":"5","author":"Mo","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.ejca.2026.117781_bib26","article-title":"Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-year follow-up results of the phase I and IIa trials","volume":"2","author":"Zhang","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejca.2026.117781_bib27","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood.V120.21.3875.3875","article-title":"Immune cell dysfunction in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"120","author":"Cole","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.117781_bib28","first-page":"18","article-title":"Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them","volume":"7","author":"Borogovac","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejca.2026.117781_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.18609\/cgti.2025.062","article-title":"Full speed ahead: how rapid CAR-T manufacturing can shape the cell therapy landscape","volume":"11","author":"Lieberman","year":"2025","journal-title":"Cell Gene Ther Insights"},{"key":"10.1016\/j.ejca.2026.117781_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1328368","article-title":"Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III\/IV melanoma","volume":"15","author":"Aleksandrova","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.117781_bib31","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2017.111","article-title":"Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use","volume":"28","author":"Lock","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ejca.2026.117781_bib32","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2026.117781_bib33","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:23:46Z","timestamp":1792599826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926015637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":33,"alternative-id":["S0959804926015637"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117781","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute and long-term outcomes of CD20-targeting CAR T-cell therapy in relapsed or refractory B-NHL: MB-CART20.1 Lymphoma phase I trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117781"}}